07.09.2010 • News

Kemira Invests €25 Milllion in China Plant

Kemira establishes a manufacturing facility in Nanjing, China to enhance customer service in the growing Chinese water treatment markets. The investment is expected to be at €25 million. The facility will be a state of the art regional production hub for a range of specialty process chemicals serving all of Kemira's customer segments.

The plant will be located in the Nanjing Chemical Industry Park (NCIP) about 300 kilometers northwest from Shanghai. "The NCIP chemical park is one of the state level chemical parks and gives easy access to raw materials and utilities. It also provides a good geographical position close to our targeted customer base with several modes of transportation for logistics. The location is also attractive for competent workforce", says Ronald Kwan, region head for Asia Pacific. "The Asian water chemistry market offers us ample opportunities for growth. Having a local manufacturing facility that works closely together with our R&D center in Shanghai will help us to tailor our offering to the local business needs", Kwan continues.

This investment underlines the strong commitment of Kemira to the growing customer base in Asia Pacific region. The facility will be 100% owned by Kemira, and will generate approximately 100 new employment opportunities in full operation. The building will start during 2011 and the facility is expected to be operational in 2012.

 

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read